524661 WELCURE

Welcure Drugs & Pharmaceuticals Share Price

 

 

Start SIP in WELCURE

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹1
  • Open Price₹0
  • Previous Close₹0
  • Volume13,355,527

Investment Returns

  • Over 1 Month -19.64%
  • Over 3 Month -26.23%
  • Over 6 Month -67.15%
  • Over 1 Year -65.38%

Smart Investing Starts Here Start SIP with Welcure Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Welcure Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 1.6
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 56
  • P/B Ratio
  • 0.4
  • Average True Range
  • 0.03
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.04
  • RSI
  • 37.76
  • MFI
  • 35.27

Welcure Drugs & Pharmaceuticals Financials

Welcure Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹0.45
-0.01 (-2.17%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹0.49
  • 50 Day
  • ₹0.56
  • 100 Day
  • ₹0.66
  • 200 Day
  • ₹0.73

Resistance and Support

0.45 Pivot Speed
  • R3 0.50
  • R2 0.48
  • R1 0.47
  • S1 0.44
  • S2 0.42
  • S3 0.41

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Welcure Drugs & Pharms. has an operating revenue of Rs. 395.59 Cr. on a trailing 12-month basis. An annual revenue growth of 29300% is outstanding, Pre-tax margin of 11% is healthy, ROE of 2% is fair but needs improvement. The company has a high debt to equity of 120%, which can be a reason to worry. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 2 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Welcure Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-05 Right Issue of Equity Shares
2025-11-27 To consider raisinf of funds Inter-alia, 1. To augment the financial resources of the Company via funds raising by way of issue of equity shares/convertible instruments/other securities through permissable modes. split from Rs. 10/- to Re. 1/-.
2025-11-13 Quarterly Results
2025-09-27 Others Inter-alia, 1. To take on record and deliberate upon the Letter of Intent (LOI) received from Telexcell Trade PTE LTD, Singapore, for a proposed acquisition of up to 25% equity stake (Revised) split from Rs. 10/- to Re. 1/-.
2025-09-02 A.G.M.
Date Purpose Remarks
2025-10-16 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.
Date Purpose Remarks
2025-10-16 Bonus Re.0.00 issue of equity shares in the ratio of 1:10 of Re. 1/-.

Welcure Drugs & Pharmaceuticals F&O

Welcure Drugs & Pharmaceuticals Shareholding Pattern

0%
91.82%
8.18%

About Welcure Drugs & Pharmaceuticals

  • NSE Symbol
  • WELCURE
  • BSE Symbol
  • 524661
  • Managing Director
  • Mr. Chintan Didawala
  • ISIN
  • INE331C01025

Similar Stocks to Welcure Drugs & Pharmaceuticals

Welcure Drugs & Pharmaceuticals FAQs

Welcure Drugs & Pharmaceuticals share price is ₹0 As on 26 December, 2025 | 01:48

The Market Cap of Welcure Drugs & Pharmaceuticals is ₹55.6 Cr As on 26 December, 2025 | 01:48

The P/E ratio of Welcure Drugs & Pharmaceuticals is 1.6 As on 26 December, 2025 | 01:48

The PB ratio of Welcure Drugs & Pharmaceuticals is 0.4 As on 26 December, 2025 | 01:48

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23